Qnexa

an anti-obesity agent

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

1.	Obesity 05/16/2012 - "[Qnexa: a new anti-obesity threat]." 04/20/2011 - "Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. " 11/01/2010 - "This reasoning has led to the development of a number of new treatments for obesity where multiple mechanisms are targeted, either by a single molecule, such as tesofensine, or through drug combinations such as qnexa, contrave, empatic, and pramlintide+metreleptin. " 03/01/2013 - "MEDLINE (1966-July 2012) was searched using the terms weight loss, obesity, phentermine and topiramate, phentermine, topiramate, Qnexa, Qsymia, and VI-0521. "
2.	Weight Loss (Weight Reduction) 03/01/2013 - "MEDLINE (1966-July 2012) was searched using the terms weight loss, obesity, phentermine and topiramate, phentermine, topiramate, Qnexa, Qsymia, and VI-0521. "

1.	Phentermine (Adipex-P)
2.	Drug Combinations
3.	Topiramate (Topamax)
4.	Qsymia
5.	Tesofensine
6.	naltrexone hydrochoride drug combination bupropion hydrochloride